Alva Review-Courier -

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor


September 29, 2019

AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Sep 28, 2019--

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today reported results from its non-clinical GLP toxicology program with first-in-class selective TGF-beta inhibitor AVID200 and evidence of TGF-beta target engagement in patients treated with this novel immuno-oncology agent at the European Society of Medical Oncology (ESMO) 2019 Annual Congress in Barcelona.

The presentation detailed for the first time that AVID200 administered at doses of ≥1 mg/kg sequestered its tar...

For access to this article please sign in or subscribe.


Reader Comments


Our Family of Publications Includes:

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2019